Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00896389 · ClinicalTrials.gov registry record · Phase 4

Salt Loading and Thiazide Intervention Study

A Phase 4 study of Hypertension, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Phase 4
Development phase
124
Enrollment target
1
Study location

NCT00896389 is a Phase 4 study of Hypertension that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 124 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00896389, a Phase 4 study of Hypertension, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Phase 4
Development phase
124 participants
Enrollment target
1
Study location

Study Summary

The investigators of this study propose to examine the relationships between STK39 (Serine Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics, hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated with the outcome of both interventions and can contribute to personalized care for hypertension.

Conditions Studied

Interventions

  • PROCEDURE Salt loading
  • DRUG Hydrochlorothiazide (HCTZ)

Study Locations (1)

Pennsylvania

  • Amish Research Clinics - Lancaster

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2009-10
Est. Completion 2013-03
Phase Phase 4

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT00896389

The ClinicalTrials.gov registry entry for NCT00896389 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Salt loading is the first listed.

NCT00896389 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00896389 about?

NCT00896389 is a clinical study titled "Salt Loading and Thiazide Intervention Study". The investigators of this study propose to examine the relationships between STK39 (Serine Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics, hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated with the outcome of both inter...

What is the current status of trial NCT00896389?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2009-10. Estimated completion is 2013-03.

What conditions does trial NCT00896389 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00896389?

The interventions under investigation include: Salt loading (PROCEDURE), Hydrochlorothiazide (HCTZ) (DRUG).

Who is sponsoring clinical trial NCT00896389?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00896389 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.